Notably, during the 5-month follow-up period after treatment completion, patients in the Sibeprenlimab group showed a trend toward a return to baseline levels of serum IgA and Gd-IgA1, suggesting that continued suppression of APRIL may be necessary to maintain clinical efficacy [ 203 ].
← all excerpts
Advancements in understanding the role of intestinal dysbacteriosis mediated mucosal immunity in IgA nephropathy.
1
—
—